A new publication referencing FOXO4-DRI research was published on July 2, 2026. The study, titled "Acylglycerol Kinase Sensitizes Glioblastoma to Temozolomide via Limiting Mitochondrial Damage Related Cellular Senescence," appears in the journal Molecular Carcinogenesis.
FOXO4-DRI remains classified as an unapproved research compound. This entry reflects only the publication record, including its title, journal, and date. No findings, conclusions, or efficacy data from the study are described here.
Readers interested in the mechanistic details, methodology, or results of this research should consult the full publication directly through the listed source. This brief does not characterize the outcomes of the study or draw any conclusions about FOXO4-DRI's effects, safety, or utility in glioblastoma or any other context.
For more background on FOXO4-DRI, including its research status and general profile, readers can refer to the compound overview.